Compile Data Set for Download or QSAR
Report error Found 32 Enz. Inhib. hit(s) with all data for entry = 5946
TargetEgl nine homolog 1(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102350(US8536181, F3 | US9278930, F3 | US10562854, No. F3)
Affinity DataIC50: 1.20E+3nMAssay Description:EGLN enzyme activity assay is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-TOF MS.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2013
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102349(US8536181, E33 | US9278930, E33 | US10562854, No. ...)
Affinity DataIC50: 2.10E+3nMAssay Description:ELISA assay using VEGF.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2013
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102345(US8536181, D10 | US9278930, D10 | US10562854, No. ...)
Affinity DataIC50: 4.40E+3nMAssay Description:EGLN enzyme activity assay is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-TOF MS.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2013
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102351(US8536181, F2 | US9278930, F2 | US10562854, No. F2)
Affinity DataIC50: 5.00E+3nMAssay Description:EGLN enzyme activity assay is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-TOF MS.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2013
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102350(US8536181, F3 | US9278930, F3 | US10562854, No. F3)
Affinity DataIC50: 7.40E+3nMAssay Description:ELISA assay using VEGF.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2013
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102339(US8536181, B5)
Affinity DataIC50: 9.00E+3nMAssay Description:EGLN enzyme activity assay is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-TOF MS.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2013
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102341(US8536181, B14 | US9278930, B14 | US10562854, No. ...)
Affinity DataIC50: 1.10E+4nMAssay Description:EGLN enzyme activity assay is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-TOF MS.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2013
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102336(US8536181, C17 | US9278930, C17 | US10562854, No. ...)
Affinity DataIC50: 1.10E+4nMAssay Description:EGLN enzyme activity assay is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-TOF MS.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2013
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102337(US8536181, C35 | US9278930, C35 | US10562854, No. ...)
Affinity DataIC50: 1.20E+4nMAssay Description:EGLN enzyme activity assay is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-TOF MS.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2013
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102338(US8536181, C14 | US9278930, C14 | US10562854, No. ...)
Affinity DataIC50: 1.20E+4nMAssay Description:EGLN enzyme activity assay is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-TOF MS.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2013
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102342(US8536181, C19 | US9278930, C19 | US10562854, No. ...)
Affinity DataIC50: 1.20E+4nMAssay Description:EGLN enzyme activity assay is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-TOF MS.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2013
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102346(US8536181, D14 | US9278930, D14 | US10562854, No. ...)
Affinity DataIC50: 1.20E+4nMAssay Description:EGLN enzyme activity assay is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-TOF MS.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2013
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102347(US8536181, C1 | US9278930, C1 | US10562854, No. C1)
Affinity DataIC50: 1.20E+4nMAssay Description:EGLN enzyme activity assay is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-TOF MS.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2013
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102343(US8536181, B9 | US9278930, B9 | US10562854, No. B9)
Affinity DataIC50: 1.26E+4nMAssay Description:ELISA assay using VEGF.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2013
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102348(US8536181, A41 | US9278930, A41 | US10562854, No. ...)
Affinity DataIC50: 1.40E+4nMAssay Description:EGLN enzyme activity assay is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-TOF MS.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2013
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102340(US8536181, C33 | US9278930, C33 | US10562854, No. ...)
Affinity DataIC50: 1.60E+4nMAssay Description:EGLN enzyme activity assay is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-TOF MS.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2013
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102348(US8536181, A41 | US9278930, A41 | US10562854, No. ...)
Affinity DataIC50: 1.66E+4nMAssay Description:ELISA assay using VEGF.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2013
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102343(US8536181, B9 | US9278930, B9 | US10562854, No. B9)
Affinity DataIC50: 1.70E+4nMAssay Description:EGLN enzyme activity assay is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-TOF MS.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2013
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102344(US8536181, A18 | US9278930, A18 | US10562854, No. ...)
Affinity DataIC50: 1.80E+4nMAssay Description:EGLN enzyme activity assay is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-TOF MS.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2013
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102346(US8536181, D14 | US9278930, D14 | US10562854, No. ...)
Affinity DataIC50: 1.90E+4nMAssay Description:ELISA assay using VEGF.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2013
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102338(US8536181, C14 | US9278930, C14 | US10562854, No. ...)
Affinity DataIC50: 2.06E+4nMAssay Description:ELISA assay using VEGF.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2013
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102349(US8536181, E33 | US9278930, E33 | US10562854, No. ...)
Affinity DataIC50: 2.10E+4nMAssay Description:EGLN enzyme activity assay is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-TOF MS.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2013
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102345(US8536181, D10 | US9278930, D10 | US10562854, No. ...)
Affinity DataIC50: 2.70E+4nMAssay Description:ELISA assay using VEGF.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2013
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102336(US8536181, C17 | US9278930, C17 | US10562854, No. ...)
Affinity DataIC50: 2.74E+4nMAssay Description:ELISA assay using VEGF.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2013
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102344(US8536181, A18 | US9278930, A18 | US10562854, No. ...)
Affinity DataIC50: 2.92E+4nMAssay Description:ELISA assay using VEGF.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2013
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102347(US8536181, C1 | US9278930, C1 | US10562854, No. C1)
Affinity DataIC50: 4.20E+4nMAssay Description:ELISA assay using VEGF.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2013
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102337(US8536181, C35 | US9278930, C35 | US10562854, No. ...)
Affinity DataIC50: 4.25E+4nMAssay Description:ELISA assay using VEGF.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2013
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102340(US8536181, C33 | US9278930, C33 | US10562854, No. ...)
Affinity DataIC50: 5.30E+4nMAssay Description:ELISA assay using VEGF.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2013
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102339(US8536181, B5)
Affinity DataIC50: 5.30E+4nMAssay Description:ELISA assay using VEGF.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2013
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102342(US8536181, C19 | US9278930, C19 | US10562854, No. ...)
Affinity DataIC50: 6.29E+4nMAssay Description:ELISA assay using VEGF.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2013
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102341(US8536181, B14 | US9278930, B14 | US10562854, No. ...)
Affinity DataIC50: 7.80E+4nMAssay Description:ELISA assay using VEGF.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2013
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102351(US8536181, F2 | US9278930, F2 | US10562854, No. F2)
Affinity DataIC50: 1.00E+5nMAssay Description:ELISA assay using VEGF.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2013
Entry Details
Go to US Patent